Previous studies have demonstrated the expression of programmed death-ligand 1 (PDL1), tumor protein 53 (TP53), and MYC protooncogene (MYC) in sarcomas and as potential targets for immunotherapy [17–19]. This evidence concerns the gene TP53 and sarcoma.